← Russell 3000 cross-section

CHRN ChronoScale Holdings Corp

Trailing twelve months to 2026-03-31 · as filed 2026-04-28, not restated
Industrials

Scale

Market cap
$3.2bn
Revenue TTM
$12m
Net income TTM
$-16m
Free cash flow
$-12m
Composite score
Sector rank
#1348

Valuation

P / E
EV / EBITDA
EV / sales
280.2
FCF yield
-0.37%
Earnings yield vs 10-yr
-5.21pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-135.7%
EBITDA margin
-119.8%
ROE
-750.7%
ROIC
Revenue growth
-34.1%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Longer term, we believe that sales of our Personal Health products have the potential to be a significant growth driver for us as we work to gain coverage by other insurance providers, expand the products' indications of use beyond SCI and optimize our reimbursement submission processes. Results of Operations The following table presents our results of operations for the three months ended March 31, 2026 and 2025 (in thousands, except percentages): (*) Not meaningful Revenue Revenue decreased $1.2 million, or 37%, for the three months ended March 31, 2026, compared to the same period of 2025. …ChronoScale Holdings Corp, 10-Q, period ended 2026-03-31, filed 2026-04-28

Read the full passage →